|
|
|
|
|
|
|
|
Live From ASCO: Time To Cool Down?: "
It's day three of ASCO and the meeting is at a fever pitch, as the National Cancer Institute's Antonio Tito Fojo wryly observed during a panel on designing randomized controlled trials to achieve meaningful benefits. Not that it's an unusual state for the world's largest meeting on the largest field of drug development.
There is the typical fervor surrounding promising early data, a few major advances to report (for instance, the melanoma data from Roche and BMS covered by among others, the NYT, WSJ, Reuters, and, of course, 'The Pink Sheet' Daily), and the meeting halls are packed with clinicians, investors, and journos. (Saturday's clinical science symposium on ovarian cancer had such throngs waiting for it to start that McCormick Place called in bouncers, from 'Armageddon Security,' nonetheless. And if you weren't in the initial crush, you probably got diverted to an overflow room. Or the second overflow room.)
Still, compared to other years, analysts aren't finding much to write home about. And, increasingly, the importance of the data being presented before packed meeting halls is being questioned. 'We need to get away from things that add cost but not value,' UnitedHealthcare's Lee Newcomer noted during a panel on health care reform.................cont'd
Image courtesy of flickrer Joe Seggiola through a creative commons license.
There is the typical fervor surrounding promising early data, a few major advances to report (for instance, the melanoma data from Roche and BMS covered by among others, the NYT, WSJ, Reuters, and, of course, 'The Pink Sheet' Daily), and the meeting halls are packed with clinicians, investors, and journos. (Saturday's clinical science symposium on ovarian cancer had such throngs waiting for it to start that McCormick Place called in bouncers, from 'Armageddon Security,' nonetheless. And if you weren't in the initial crush, you probably got diverted to an overflow room. Or the second overflow room.)
Still, compared to other years, analysts aren't finding much to write home about. And, increasingly, the importance of the data being presented before packed meeting halls is being questioned. 'We need to get away from things that add cost but not value,' UnitedHealthcare's Lee Newcomer noted during a panel on health care reform.................cont'd
Image courtesy of flickrer Joe Seggiola through a creative commons license.
© Copyright 2007-2011 Windhover Information Inc.
www.windhover.com/blog
"
www.windhover.com/blog
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.